ALSO READZydus gets US health regulator nod for hypertension drug Nifedipine Dr Reddy's recalls single lot of breast cancer drug Docetaxel from US Lupin eyes share of $48 mn market with anti-infection capsule launch in US UPSC-2017 Invites Applications For Junior Scientific Officer (Chemistry) Microscope trailblazers win 2017 Nobel prize for Chemistry
Drug firm Lupin today said it has launched in the US market its generic Oseltamivir Phosphate capsules, used for treatment of influenza. The company said in a BSE filing that it has launched its tablets after receiving the approval from the United States Food and Drug Administration (USFDA). The capsules, in the strengths of 30 mg, 45 mg and 75 mg, are generic versions of Hoffman-La Roche Inc's Tamiflu capsules in the same strengths, it added. The product is "indicated for the treatment of acute, uncomplicated influenza A and B in patients two weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients one year and older", Lupin said. The capsules had annual sales of about USD 518 million in the US as per IQVIA MAT December 201 data, it added. Lupin Ltd stock was trading 2.81 per cent higher at Rs 843.95 in the afternoon trade on BSE.